134 related articles for article (PubMed ID: 38355016)
1. Development of a high-throughput screening platform to identify new therapeutic agents for Medulloblastoma Group 3.
Fallon I; Hernando H; Almacellas-Rabaiget O; Marti-Fuster B; Spadoni C; Bigner DD; Méndez E
SLAS Discov; 2024 Mar; 29(2):100147. PubMed ID: 38355016
[TBL] [Abstract][Full Text] [Related]
2. Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137.
Wang J; Sui Y; Li Q; Zhao Y; Dong X; Yang J; Liang Z; Han Y; Tang Y; Ma J
Cell Death Dis; 2020 Dec; 11(12):1029. PubMed ID: 33268769
[TBL] [Abstract][Full Text] [Related]
3. Dissecting super-enhancer driven transcriptional dependencies reveals novel therapeutic strategies and targets for group 3 subtype medulloblastoma.
Li M; Han Y; Wang C; Kang W; Jiang W; Zhang L; Tang Y
J Exp Clin Cancer Res; 2022 Oct; 41(1):311. PubMed ID: 36273157
[TBL] [Abstract][Full Text] [Related]
4. Subgroup-Enriched Pathways and Kinase Signatures in Medulloblastoma Patient-Derived Xenografts.
Leskoske KL; Garcia-Mansfield K; Sharma R; Krishnan A; Rusert JM; Mesirov JP; Wechsler-Reya RJ; Pirrotte P
J Proteome Res; 2022 Sep; 21(9):2124-2136. PubMed ID: 35977718
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma.
Kieran MW; Chisholm J; Casanova M; Brandes AA; Aerts I; Bouffet E; Bailey S; Leary S; MacDonald TJ; Mechinaud F; Cohen KJ; Riccardi R; Mason W; Hargrave D; Kalambakas S; Deshpande P; Tai F; Hurh E; Geoerger B
Neuro Oncol; 2017 Oct; 19(11):1542-1552. PubMed ID: 28605510
[TBL] [Abstract][Full Text] [Related]
6. An effective kinase inhibition strategy for metastatic recurrent childhood medulloblastoma.
Adile AA; Bakhshinyan D; Suk Y; Uehling D; Saini M; Aman A; Magolan J; Subapanditha MK; McKenna D; Chokshi C; Savage N; Kameda-Smith MM; Venugopal C; Singh SK
J Neurooncol; 2023 Jul; 163(3):635-645. PubMed ID: 37354357
[TBL] [Abstract][Full Text] [Related]
7. Molecular and functional profiling of chemotolerant cells unveils nucleoside metabolism-dependent vulnerabilities in medulloblastoma.
Mariotto E; Rampazzo E; Bortolozzi R; Rruga F; Zeni I; Manfreda L; Marchioro C; Canton M; Cani A; Magni R; Luchini A; Bresolin S; Viola G; Persano L
Acta Neuropathol Commun; 2023 Nov; 11(1):183. PubMed ID: 37978570
[TBL] [Abstract][Full Text] [Related]
8. Salvage therapy for progressive, treatment-refractory or recurrent pediatric medulloblastoma: a systematic review protocol.
Adile AA; Kameda-Smith MM; Bakhshinyan D; Banfield L; Salim SK; Farrokhyar F; Fleming AJ
Syst Rev; 2020 Mar; 9(1):47. PubMed ID: 32127049
[TBL] [Abstract][Full Text] [Related]
9. Targeting cyclin-dependent kinase 9 sensitizes medulloblastoma cells to chemotherapy.
Song H; Bhakat R; Kling MJ; Coulter DW; Chaturvedi NK; Ray S; Joshi SS
Biochem Biophys Res Commun; 2019 Dec; 520(2):250-256. PubMed ID: 31594641
[TBL] [Abstract][Full Text] [Related]
10. Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma.
Morfouace M; Shelat A; Jacus M; Freeman BB; Turner D; Robinson S; Zindy F; Wang YD; Finkelstein D; Ayrault O; Bihannic L; Puget S; Li XN; Olson JM; Robinson GW; Guy RK; Stewart CF; Gajjar A; Roussel MF
Cancer Cell; 2014 Apr; 25(4):516-29. PubMed ID: 24684846
[TBL] [Abstract][Full Text] [Related]
11. MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma.
Pitolli C; Marini A; Guerra M; Pieraccioli M; Marabitti V; Palluzzi F; Giacò L; Tamburrini G; Cecconi F; Nazio F; Sette C; Pagliarini V
J Exp Clin Cancer Res; 2023 Aug; 42(1):214. PubMed ID: 37599362
[TBL] [Abstract][Full Text] [Related]
12. Molecular and in vivo characterization of cancer-propagating cells derived from MYCN-dependent medulloblastoma.
Ahmad Z; Jasnos L; Gil V; Howell L; Hallsworth A; Petrie K; Sawado T; Chesler L
PLoS One; 2015; 10(3):e0119834. PubMed ID: 25785590
[TBL] [Abstract][Full Text] [Related]
13. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
Henssen A; Thor T; Odersky A; Heukamp L; El-Hindy N; Beckers A; Speleman F; Althoff K; Schäfers S; Schramm A; Sure U; Fleischhack G; Eggert A; Schulte JH
Oncotarget; 2013 Nov; 4(11):2080-95. PubMed ID: 24231268
[TBL] [Abstract][Full Text] [Related]
14. BMI1 is a therapeutic target in recurrent medulloblastoma.
Bakhshinyan D; Venugopal C; Adile AA; Garg N; Manoranjan B; Hallett R; Wang X; Mahendram S; Vora P; Vijayakumar T; Subapanditha M; Singh M; Kameda-Smith MM; Qazi M; McFarlane N; Mann A; Ajani OA; Yarascavitch B; Ramaswamy V; Farooq H; Morrissy S; Cao L; Sydorenko N; Baiazitov R; Du W; Sheedy J; Weetall M; Moon YC; Lee CS; Kwiecien JM; Delaney KH; Doble B; Cho YJ; Mitra S; Kaplan D; Taylor MD; Davis TW; Singh SK
Oncogene; 2019 Mar; 38(10):1702-1716. PubMed ID: 30348991
[TBL] [Abstract][Full Text] [Related]
15. Pediatric medulloblastoma in the molecular era: what are the surgical implications?
Kameda-Smith MM
Cancer Metastasis Rev; 2020 Mar; 39(1):235-243. PubMed ID: 32095940
[TBL] [Abstract][Full Text] [Related]
16. Characterization of an RNA binding protein interactome reveals a context-specific post-transcriptional landscape of MYC-amplified medulloblastoma.
Kameda-Smith MM; Zhu H; Luo EC; Suk Y; Xella A; Yee B; Chokshi C; Xing S; Tan F; Fox RG; Adile AA; Bakhshinyan D; Brown K; Gwynne WD; Subapanditha M; Miletic P; Picard D; Burns I; Moffat J; Paruch K; Fleming A; Hope K; Provias JP; Remke M; Lu Y; Reya T; Venugopal C; Reimand J; Wechsler-Reya RJ; Yeo GW; Singh SK
Nat Commun; 2022 Dec; 13(1):7506. PubMed ID: 36473869
[TBL] [Abstract][Full Text] [Related]
17. Signaling pathway and molecular subgroups of medulloblastoma.
Li KK; Lau KM; Ng HK
Int J Clin Exp Pathol; 2013; 6(7):1211-22. PubMed ID: 23826403
[TBL] [Abstract][Full Text] [Related]
18. Medulloblastoma: Molecular understanding, treatment evolution, and new developments.
Liu X; Ding C; Tan W; Zhang A
Pharmacol Ther; 2020 Jun; 210():107516. PubMed ID: 32105673
[TBL] [Abstract][Full Text] [Related]
19. Glabrescione B delivery by self-assembling micelles efficiently inhibits tumor growth in preclinical models of Hedgehog-dependent medulloblastoma.
Infante P; Malfanti A; Quaglio D; Balducci S; De Martin S; Bufalieri F; Mastrotto F; Basili I; Garofalo M; Lospinoso Severini L; Mori M; Manni I; Moretti M; Nicoletti C; Piaggio G; Caliceti P; Botta B; Ghirga F; Salmaso S; Di Marcotullio L
Cancer Lett; 2021 Feb; 499():220-231. PubMed ID: 33249196
[TBL] [Abstract][Full Text] [Related]
20. Functional Precision Medicine Identifies New Therapeutic Candidates for Medulloblastoma.
Rusert JM; Juarez EF; Brabetz S; Jensen J; Garancher A; Chau LQ; Tacheva-Grigorova SK; Wahab S; Udaka YT; Finlay D; Seker-Cin H; Reardon B; Gröbner S; Serrano J; Ecker J; Qi L; Kogiso M; Du Y; Baxter PA; Henderson JJ; Berens ME; Vuori K; Milde T; Cho YJ; Li XN; Olson JM; Reyes I; Snuderl M; Wong TC; Dimmock DP; Nahas SA; Malicki D; Crawford JR; Levy ML; Van Allen EM; Pfister SM; Tamayo P; Kool M; Mesirov JP; Wechsler-Reya RJ
Cancer Res; 2020 Dec; 80(23):5393-5407. PubMed ID: 33046443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
